诊断提供者类型对新诊断亨廷顿病患者纵向护理的影响

数据集获取（Figshare）

• 源站标题：The impact of diagnosing provider type on longitudinal care for patients with newly diagnosed Huntington’s disease
• DOI：10.6084/m9.figshare.27179970.v2
• 发布日期：2024-10-23
• 文件数：4 个
• 文件总体积：126.02 KB
• 源站页面：https://tandf.figshare.com/articles/dataset/The_impact_of_diagnosing_provider_type_on_longitudinal_care_for_patients_with_newly_diagnosed_Huntington_s_Disease/27179970

命令行下载

curl -L -o "ijme_a_2412470_sm8829.docx" "https://ndownloader.figshare.com/files/49642998"
curl -L -o "ijme_a_2412470_sm4800.jpeg" "https://ndownloader.figshare.com/files/49643001"
curl -L -o "ijme_a_2412470_sm4794.docx" "https://ndownloader.figshare.com/files/49643004"
curl -L -o "ijme_a_2412470_sm4793.docx" "https://ndownloader.figshare.com/files/49643007"

文件清单

• ijme_a_2412470_sm8829.docx（11.86 KB）
• ijme_a_2412470_sm4800.jpeg（73.61 KB）
• ijme_a_2412470_sm4794.docx（23.39 KB）
• ijme_a_2412470_sm4793.docx（17.15 KB）

文件总体积 126.02 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

This study evaluated the association between provider types for patients with newly diagnosed Huntington’s disease (HD) and healthcare resource utilization (HCRU), costs, and treatment patterns.
This retrospective analysis used MarketScan databases (1 January 2017–31 December 2021) to identify provider types who diagnosed and managed US adult patients with HD. Patients with continuous enrollment 6 months pre- and 12 months post-diagnosis were included. Outcomes evaluated over 12 months post-diagnosis included hospitalizations, outpatient visits, antipsychotic or vesicular monoamine transporter 2 (VMAT2) inhibitor use, and total healthcare costs.
Three hundred and forty eligible patients had a mean age at diagnosis of 49 years. 56.5% were female; 71.5% had a Charlson Comorbidity Index of 0. Patients were diagnosed by neurologists (48.5%), primary care providers (PCPs) (35.6%), psychiatrists (3.5%), or other providers (12.4%). Patients diagnosed by PCPs or neurologists received significantly more follow-ups by the same diagnosing provider type (p vs. those diagnosed by PCPs (−$2,256; p vs. PCPs, similar proportions received antipsychotics within the first year (55 vs. 52%, respectively); more patients managed by neurologists received VMAT2 inhibitors (12 vs. 7%, respectively).
Our study includes limitations inherent to retrospective claims studies.
Patients with HD are most often diagnosed by neurologists or PCPs; the same diagnosing provider type typically manages follow-up. Patients diagnosed by neurologists had significantly fewer HD-related outpatient visits, lower HD-related non-drug costs, and more frequently received VMAT2 inhibitors vs. those diagnosed by PCPs. Our findings show an integrated care team may provide evidence-based, personalized care for patients with HD.
Huntington’s disease is a rare disease that is caused by changes in genes. Symptoms of Huntington’s disease are irritability, depression, loss of memory, and issues with movement. The symptoms are different for each person and can happen at different times during the disease. A team of doctors that can help with all the symptoms is important for treating Huntington’s disease. In our stu

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.27179970.v2（source: https://tandf.figshare.com/articles/dataset/The_impact_of_diagnosing_provider_type_on_longitudinal_care_for_patients_with_newly_diagnosed_Huntington_s_Disease/27179970）。